Cannabis -vs- Inflammatory Eye Disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1772142: Cannabinoids have the potential of becoming a useful treatment for glaucoma, as they seem to have neuroprotective properties and effectively reduce intraocular pressure. However, several challenges need to be overcome, including the problems associated with unwanted systemic side effects (psychotropic, reduction in systemic blood pressure), possible tolerance, and the difficulty in formulating a stable and effective topical preparation. Some cannabinoids such as HU-211 and cannabidiol do not have psycotropic effects, while maintaining their IOP lowering action, so that further research on these compounds would be desirable. Tolerance may develop after repeated use of cannabinoids.30 However, tolerance might be beneficial if it develops only or preferentially to unwanted side effects. There has been recent progress in the use of microemulsions and cyclodextrins to overcome the barriers in ocular penetration of topically applied cannabinoids.
Other possible applications of cannabinoids in ophthalmology could be explored. Age related macular degeneration (AMD) is the leading cause of blindness in the United Kingdom. Perhaps the potent antioxidant properties of the cannabinoids may be beneficial in AMD, offering a possible alternative to established antioxidant supplements.68 Cannabinoids have been shown to inhibit angiogenesis, leading to a decrease in the expression of proangiogenic factors such as VEGF.69 Evidence suggests that VEGF plays a major part in the development of choroidal neovascularisation in AMD, and clinical trials using anti-VEGF therapies are being conducted.70 The CB2 receptors are also under intense investigation for their possible immunomodulatory effects.71 The anti-inflammatory properties of CB2 receptor agonists might also prove to be of therapeutic relevance in different forms of inflammatory eye disease.